J. Catalano

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +10

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

Harry Iland, K. F. Bradstock, John F. Seymour et al. · Haematologica · 2011 · 59 citations · Full text

An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.

Robert Marcus, Kevin Imrie, Andrew Belch et al. · Ghent University Academic Bibliography (Ghent University) · 2003 · 42 citations

Lymphoid Neoplasia, International Multi-centre, Medicine +9

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Journal of Clinical Oncology · 2011 · 39 citations

Antifibrotic Therapy, Immunodeficiencies, Immunology +25

Results of a Double Blind Placebo Controlled Study of Ondansetron as an Antiemetic During Total Body Irradiation in Patients Undergoing Bone Marrow Transplantation

Campbell Tiley, R Powles, J. Catalano et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1992 · 32 citations

Transplantation, Oncology, Radiation Therapy +11